2005
DOI: 10.1182/blood-2005-03-1310
|View full text |Cite
|
Sign up to set email alerts
|

A phase 1/2 trial of high-dose yttrium-90-ibritumomab tiuxetan in combination with high-dose etoposide and cyclophosphamide followed by autologous stem cell transplantation in patients with poor-risk or relapsed non-Hodgkin lymphoma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
87
1
7

Year Published

2007
2007
2015
2015

Publication Types

Select...
5
5

Relationship

0
10

Authors

Journals

citations
Cited by 191 publications
(99 citation statements)
references
References 28 publications
3
87
1
7
Order By: Relevance
“…17 The initial studies using radioimmunotherapy in combination with high-dose chemotherapy and autologous SCT show promising results. [18][19][20][21][22] In this study, we explored the use of standard-dose Zevalin combined with RIC and allogeneic SCT in patients with chemorefractory lymphoma expected to have poor outcome with standard SCT.…”
Section: Introductionmentioning
confidence: 99%
“…17 The initial studies using radioimmunotherapy in combination with high-dose chemotherapy and autologous SCT show promising results. [18][19][20][21][22] In this study, we explored the use of standard-dose Zevalin combined with RIC and allogeneic SCT in patients with chemorefractory lymphoma expected to have poor outcome with standard SCT.…”
Section: Introductionmentioning
confidence: 99%
“…Efforts should be made to include these patients in clinical trials, perhaps testing new drugs in the relapsing setting or the use of radioimmunoconjugates as part of the conditioning regimen. [33][34][35] The prognostic system proposed here is practical and powerful but needs to be validated in an independent cohort. Although clinically relevant, a prognostic model constituted by IPI-R and TTR will not be perfect, in part because these markers are likely surrogates of a tumor's capacity to proliferate, migrate and resist the lethaal effects of chemotherapy.…”
Section: Discussionmentioning
confidence: 99%
“…These findings indicate that the use of novel therapeutics should be explored in attempts to improve the outcome in such patients. Recently, the use of immunotherapy or radioimmunotherapy (Rituximab, Y-ibritumomab) as part of the conditioning regimen for ASCT has produced promising results with improved disease control (24,25). The results of these newer approaches are expected to improve the outcome in these patients.…”
Section: Discussionmentioning
confidence: 99%